IGF1R and breast cancer: Our data demonstrate that patients with loss of IGF-1R on CTCs have a significantly worse outcome than patients with IGF-1R expression on CTCs, providing a possible clue for improved patient stratification strategies aimed at metabolic targeting in advanced BC.152 Overall, the relationship between IR, metabolic impairment, the underlying chronic inflammatory status and cancer needs to be extensively evaluated to better develop a strategy for “metabolic targeting”.